keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Published 1 year ago • 3.2K plays • Length 4:20Download video MP4
Download video MP3
Similar videos
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
4:50
triple negative breast cancer update: immunotherapy in stage 2-3 tnbc (keynote 522 update)
-
27:45
treatment options for triple-negative breast cancer prof. peter schmid
-
3:58
parp inhibitors plus immunotherapy for advanced triple negative breast cancer
-
8:05
keynote-522: immune therapy and chemotherapy in patients with early triple negative breast cancer
-
1:29
immunotherapy keytruda shows benefit in early triple-negative breast cancer
-
13:44
first chemo treatment for tnbc. keynote 522
-
11:21
how i was diagnosed with triple negative breast cancer
-
12:12
a long overdue update! triple negative breast cancer
-
1:43
dr. rugo on the results of the keynote-522 trial in tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
2:32
keynote-890: tavo in combination with keytruda for late-stage triple negative breast cancer patients
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
8:45
keytruda phase 3 keynote-522 trial data
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
4:22
immunotherapy in early triple-negative breast cancer: new data and future directions
-
1:08
neoadjuvant durvalumab shows benefit in triple-negative breast cancer
-
5:16
study of sacituzumab govitecan for triple-negative breast cancer
-
5:08
advancing treatment in triplenegativebreastcancer insights from the keynote 522 trial
-
2:46
real-world insights on pembrolizumab for er-low triple-negative breast cancer
-
1:45:12
50- triple negative breast cancer